[go: up one dir, main page]

WO2008004992A3 - Transdermal formulations containing hepatitis c virus immunogens and an ethoxylated oil - Google Patents

Transdermal formulations containing hepatitis c virus immunogens and an ethoxylated oil Download PDF

Info

Publication number
WO2008004992A3
WO2008004992A3 PCT/US2006/020101 US2006020101W WO2008004992A3 WO 2008004992 A3 WO2008004992 A3 WO 2008004992A3 US 2006020101 W US2006020101 W US 2006020101W WO 2008004992 A3 WO2008004992 A3 WO 2008004992A3
Authority
WO
WIPO (PCT)
Prior art keywords
formulations containing
transdermal delivery
transdermal formulations
ethoxylated oil
containing hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/020101
Other languages
French (fr)
Other versions
WO2008004992A2 (en
Inventor
Frederick Jordan
Matti Sallberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tripep AB
ORYXE
Original Assignee
Tripep AB
ORYXE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tripep AB, ORYXE filed Critical Tripep AB
Anticipated expiration legal-status Critical
Publication of WO2008004992A2 publication Critical patent/WO2008004992A2/en
Publication of WO2008004992A3 publication Critical patent/WO2008004992A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Embodiments of the present invention relate to the discovery of several formulations of a transdermal delivery composition that delivers low and high molecular weight compounds, preferably hepatitis C virus (HCV) antigens and immunogens to a subject. Aspects of the invention include said transdermal delivery compositions, transdermal delivery devices for. providing said compositions to subjects in need thereof and methods of making and using the foregoing.. Preferably, the HCV antigen is NS3/4A. The immunogenic composition can further comprise ribavirin as an adjuvant.
PCT/US2006/020101 2005-05-25 2006-05-24 Transdermal formulations containing hepatitis c virus immunogens and an ethoxylated oil Ceased WO2008004992A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68503505P 2005-05-25 2005-05-25
US60/685,035 2005-05-25

Publications (2)

Publication Number Publication Date
WO2008004992A2 WO2008004992A2 (en) 2008-01-10
WO2008004992A3 true WO2008004992A3 (en) 2009-01-29

Family

ID=38895039

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/020101 Ceased WO2008004992A2 (en) 2005-05-25 2006-05-24 Transdermal formulations containing hepatitis c virus immunogens and an ethoxylated oil

Country Status (1)

Country Link
WO (1) WO2008004992A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10076491B2 (en) * 2013-02-05 2018-09-18 Nitto Denko Corporation Vaccine composition

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002013855A2 (en) * 2000-08-17 2002-02-21 Tripep Ab Vaccines containing ribavirin and methods of use thereof
WO2004048402A2 (en) * 2002-11-26 2004-06-10 Tripep Ab A hepatitis c virus codon optimized non-structural ns3/4a fusion gene
WO2005039464A1 (en) * 2003-10-10 2005-05-06 Oryxe Transdermal high and low molecular weight compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002013855A2 (en) * 2000-08-17 2002-02-21 Tripep Ab Vaccines containing ribavirin and methods of use thereof
WO2004048402A2 (en) * 2002-11-26 2004-06-10 Tripep Ab A hepatitis c virus codon optimized non-structural ns3/4a fusion gene
WO2005039464A1 (en) * 2003-10-10 2005-05-06 Oryxe Transdermal high and low molecular weight compounds

Also Published As

Publication number Publication date
WO2008004992A2 (en) 2008-01-10

Similar Documents

Publication Publication Date Title
WO2008014979A3 (en) NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT
WO2008021936A3 (en) Hepatitis c virus inhibitors
WO2004087153A3 (en) Use of organic compounds for immunopotentiation
DE60121136D1 (en) Proteasome-INFLUENZA VIRUS VACCINE COMPOSITION
ZA200900935B (en) Hepatitis C virus inhibitors
WO2007052155A3 (en) Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
WO2008021927A3 (en) Hepatitis c virus inhibitors
DK2468300T3 (en) Vaccine composition containing synthetic adjuvant
EA201001276A1 (en) HEPATITIS C VIRUS INHIBITORS
WO2007052058A8 (en) Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
WO2008039267A3 (en) Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
WO2009143457A3 (en) Vaccine composition containing synthetic adjuvant
UA88909C2 (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, pharmaceutical composition based thereon and using the same
EP2589602A3 (en) Development of dengue virus vaccine components
AR061894A1 (en) VACCINES FOR MALARIA
DK1898948T3 (en) Polyriboinosinic acid-polyribocytidylic acid-based adjuvant
CU23759A3 (en) IMMUNOGENIC COMPOSITIONS
AU2003246373A8 (en) Recombinant measles viruses expressing epitopes of antigens of rna viruses - use for the preparation of vaccine compositions
MA32821B1 (en) VACCINE COMBINALLY COMBINED AGAINST COQUELUCHE (WHOLE CELLULAR VACCINE)
SG160336A1 (en) Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients
WO2009080715A3 (en) Vaccines for malaria
WO2006138568A3 (en) Multivalent entrain-and-amplify immunotherapeutics for carcinoma
WO2006074303A3 (en) Delivery vehicles, bioactive substances and viral vaccines
WO2005107796A3 (en) Cellular permissivity factor for viruses, and uses thereof
WO2008008541A8 (en) Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06851396

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06851396

Country of ref document: EP

Kind code of ref document: A2